Open to Enrollment Studies

Cancer

BREAST CANCER COLLABORATIVE REGISTRY
An investigator-initiated, multisite institutional, non-interventional trial sponsored by the University of Nebraska Medical Center. The registry is focused on the collection of detailed information of participants to help create a resource that will be helpful to researchers in future studies related to breast cancer. It is the hope that future research using information from this registry will lead to improved diagnosis, prevention and treatment of breast cancers.
Principal investigator: Melissa Kaptanian, MD
Contact:  Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org

CHIESI CUSA-081-HEM (READY-1) Trial
A Phase 3, Randomized, Double-Blind, Active and Placebo- Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
Principal Investigator, Elise Anderes, MD
Contact: Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org

EMBRACE – RB-AG-PLT-01
Evaluation of Novel Blood-Based Biomarkers for Detection of Breast Cancer (EMBRACE)
Principal investigator: Melissa Kaptanian, MD
Contact:  Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org

MONTANA CANCER CONSORTIUM (NCORP)TRIALS
The Montana Cancer Consortium is a NCI Community Oncology Research Program (NCORP) that gives patients at Logan Health access to more than 80 clinical trials for various disease sites, including brain, breast, lung, gastrointestinal, genitourinary, gynecological, lymphomas, melanoma, multiple myeloma and neuroendocrine diseases. These trials are sponsored by cooperative groups in the U.S. (i.e., ALLIANCE, ECOG-ACRIN, NRG, SWOG) and the National Cancer Institute (NCI). This includes treatment trials, cancer prevention trials and cancer care delivery research (CCDR). For more information on the open trials available, visit www.mtcancer.org
Site Principal Investigator, Elise Anderes, MD
Contact: Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org

Cardiology

AEGIS II
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel group
Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
Principal investigator: Eve Gillespie, MD, PhD
Contact: Lucia Kufa, MS, CCRC, (406) 607-6017 or lkufa@logan.org

Bio-AffectDX
Atrial Fibrillation associated with Heart Failure treated by BIOTRONIK’s CRT-DX System
Principal investigator: Matt Brunson, MD 
Contacts: Lucia Kufa, MS, CCRC at (406) 607-8017 or lkufa@logan.org

CARE-HK in HF Registry HQ-NIS-CHF-07.2020
Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalaemia or at High Risk of Hyperkalaemia
Principal investigator: Eve Gillespie, MD, PhD
Contact: Lucia Kufa, MS, CCRC, (406) 607-6017 or lkufa@logan.org

FineArts-HF
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)
Principal Investigator: Eve Gillespie, MD, PhD
Contact: Lucia Kufa, MS, CCRC (406) 607-8017or lkufa@logan.org.  
 
VICTOR HFrEF – MK1242-035
A Pivatol Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Chronic Heart Failure With Reduced Ejection Fraction
Principal Investigator: Eve Gillespie, MD, PhD
Contact: Lucia Kufa, MS, CCRC (406) 607-8017or lkufa@logan.org.  

COVID-19

I-Spy COVID-19
An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
Principal Investigator: Timothy Obermiller, MD
Contact:  Mandy Bartlett, RN, CCRC @ 406-607-8021 abartlett@logan.org
or Lucia Kufa, MS, CCRC, (406) 607-8017or lkufa@logan.org  

Endocrinology

ARO-APOC3-2001
A Double-Blind, Placeco-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia.
Principal Investigator: Jose de Souza, MD
Contact: (406) 752-7636 or email DEPTresearch@logan.org
 
J1I-MC-GZBD
A Phase 2 Study on Once-Weekly LY3437943 Compared with Placebo and Dulaglutide in Participants with Type 2 Diabetes
Principal Investigator: Jose de Souza, MD
Contact: (406) 752-7636 or email DEPTresearch@logan.org 

Gastroenterology

Allakos AK002-014
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis
Principal Investigator: Daniel Lustig, MD – Pediatrics
                                      William Simpson, MD – Adult
Contact Mandy Bartlett, RN, CCRC, (406) 607-8021 or abartlett@logan.org  
 
Allakos AK002-023
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety, Tolerability and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects with Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis Who Have an Inadequate Response with, Lost Response to, or Where Intolerant to Standard Therapies.
Principal Investigator: William Simpson, MD – Adult
Contact David Stufflebeam, (406) 607-8018 or dstufflebeam@logan.org

Rheumatology

INSPIRE 1 – TILD-19-07
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or jwyatt@logan.org
 
AbbVie M20-466
 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or jwyatt@logan.org
 
APEX PSA – CNTO1959PSA3004
 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutanuously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthristis. APEX
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or jwyatt@logan.org
 
RECAST SLE – VIB7734 P2.S1
 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety of VIB7734 for the Treatment of Moderate ro Severely Active Systemic Lupus Arythematosus.
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or jwyatt@logan.org